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Abstract 
 
Background 
Cancer incidence increases exponentially with advancing age, cancer patients live longer 
than in the past, and many new treatments focus on stabilizing disease and health related 
quality of life (HRQOL). The objective of this study is to examine how cancer affects 
SDWLHQWV¶ HRQOL and whether their HRQOL is age-dependent.  
 
Methods 
Data from 25 European Organisation for Research and Treatment of Cancer (EORTC) 
randomized controlled trials was pooled. EORTC QLQ-C30 mean scores for the cancer 
cohort and five general population cohorts were compared to assess the impact of cancer 
on patients¶ HRQOL.  Within the cancer cohort, multiple linear regressions were used to 
investigate the association between age and HRQOL, adjusted for gender, WHO 
performance status (PS), distant metastasis and stratified by cancer site.  A difference of 
10 points on the 0-100 scale was considered clinically important.  
 
Results 
Cancer patients generally have worse HRQOL compared to the general population, but 
the specifically impaired HRQOL domains vary by age. When comparing the cancer 
versus the general population cohort, role functioning is lower in all age categories. 
Young cancer patients have worse financial problems and social functioning, while older 
cancer patients have more appetite loss, constipation, and poorer emotional functioning. 
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Within the cancer cohort, HRQOL was worse with increasing age for physical, cognitive 
functioning and constipation, and better with increasing age for social, role and emotional 
functioning, insomnia and financial problems.  
 
Conclusion 
HRQOL is impaired in cancer patients compared to the general population, but the 
impact on specific HRQOL domains varies by age. Within the cancer population, some 
HRQOL components improve by age while others deteriorate. Optimal care for older 
cancer patients should target HRQOL domains most relevant to this population.  
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Introduction 
 
To improve the care of cancer patients, it is essential for health care professionals to 
understand how the disease and its treatment affect cancer SDWLHQWV¶health-related quality 
of life (HRQOL). Health care professionals can incorporate HRQOL in shared decision 
making to enhance patient management.1 Several HRQOL questionnaires exist, including 
the 30-item Quality of Life Questionnaire Core model developed by the European 
Organization for Research and Treatment of Cancer (EORTC QLQ-C30).    
 
Reference values for the EORTC QLQ-C30 are calculated within certain general 
populations and can be used for baseline HRQOL in cancer patients. These values are 
based on population studies from Sweden2, the Netherlands3, Germany4,5 and Norway6. 
The data show how increasing age is associated with decreasing HRQOL for all 
functioning scales. However the relationship is less clear for the symptoms scales. Within 
cancer studies, patients¶ DJH KDV also been demonstrated7,8,9  to be an important factor 
contributing to HRQOL impairment. However the magnitude of this relationship is not 
well established.10, 11  
 
Knowing that cancer occurs later in life, with nearly 80% of all cancers diagnosed among 
individuals aged 55 and older, a clearer picture is needed regarding differential HRQOL 
effects of cancer by age and possible therapies tailored to older cancer patients given their 
HRQOL. It is well-known that elderly patients do not tolerate chemotherapy as well as 
their younger counterparts and express a higher symptom burden, due to the higher 
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prevalence of comorbid conditions and organ failure. In addition, the biology of some 
cancers changes with age, e.g. myeloid leukemia,12 such that specific trials are needed for 
the older age group. Further concerns relate to comorbidities and physiological changes 
associated with aging that may influence anticancer drug metabolism and toxicity.13,14  
 
Above concerns raise the need for specific trials for the older age group.15,16,17  The 
availability of new molecularly targeted agents and newly improved existing agents has 
expanded the range of treatments options available for elderly cancer patients.18 Some of 
these agents have shown better tolerability and a better safety profile19 and may therefore 
provide new options for systemic therapy suitable to the elderly cancer population.  
 
In this study, we investigated HRQOL in cancer patients compared to a population that 
did not have cancer; and the impact of ageing on cancer-related HRQOL. The specific 
objectives of this study were to examine 1) the HRQOL differences on the EORTC QLQ-
C30 HRQOL domains between cancer patients and the general population and 2) how 
age influences the HRQOL of cancer patients, adjusted for known confounding factors.  
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Methods 
 
General Population Cohorts 
For the general population cohort, five population samples were pooled derived from 
Swedish2, Dutch3, German4,5,  Norwegian6surveys. All samples were representative to the 
general population with regard to age and sex. All respondents completed the EORTC 
QLQ-C30. The published unadjusted crude EORTC QLQ-C30 mean scores for specific 
age and gender categories are used. Only those general population cohorts that could be 
compared given their published age categories were included in the analysis. 
 
Cancer Cohorts 
For the cancer cohort, we pooled individual patient data from 25 closed phase 3 
randomized controlled trials conducted by the EORTC. Our study included 10 cancer 
sites: colorectal (three trials), lung (five), oesophageal (one), ovarian (two), prostate 
(four), testicular (one), breast (three), head & neck (two), melanoma (three) and pancreas 
(one). HRQOL was assessed as a secondary endpoint using the EORTC QLQ-C30. 
Patients eligible for the study were those who had completed a valid baseline EORTC 
questionnaire, using established EORTC guidelines. Baseline data reflect HRQOL 
following diagnosis but prior to the beginning of protocol therapy. Patients may have had 
prior treatment or therapies before entering the trial - some never had anti-cancer 
treatment, others had prior surgery, and still others may have had multiple rounds of 
palliative chemotherapy or radiotherapy before entering these trials. 
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The EORTC QLQ-C30 incorporates five functioning scales (physical, role, cognitive, 
emotional and social functioning); three symptom scales (fatigue, pain, and nausea and 
vomiting); and a global health scale.20  The remaining single items assess additional 
symptoms commonly reported by cancer patients: dyspnoea, appetite loss, sleep 
disturbance, constipation and diarrhoea, as well as the perceived financial impact of the 
disease and treatment. For ease of statistical interpretation and psychometric validation, 
all scale and item scores were linearly transformed to a 0 to 100 scale. For the five 
functional scales and the global health scale, a higher score represents a better level of 
functioning. For the symptom-oriented scales and items, a higher score corresponds to a 
higher level of symptom burden.21 
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Statistical Analyses 
 
To allow for comparison between the general population and cancer cohort, crude 
unadjusted mean scores were calculated for three available age categories:  <50 years, 50-
70 years and >70 years. Comparison of the mean scores was performed using VWXGHQWV¶t-
test. The t-test has a two-sided significance level of 0.05. Differences of 10 points on the 
0-100 scale are considered clinically important as suggested by Osoba.22 
 
To assess the effect of age on the EORTC QLQ-C30 scores in the cancer cohort, multiple 
linear regression models were used adjusted for gender, World Health Organization 
(WHO) PS, distant metastases and stratified by cancer site. WHO PS was dichotomised 
(0-1 versus 2-3UHSUHVHQWLQJ³JRRG´YHUVXV³EDG´SHUIRUPDQFHVWDtus. Distant metastasis 
status was classified LQWR µno¶ versus µyes¶, according to the TNM classification 
developed by the International Union Against Cancer.23.  
 
The relationships were assessed via WKH SRLQW HVWLPDWH UHJUHVVLRQ FRHIILFLHQW ȕ RI WKH
mean of each HRQOL scale, its 95% confidence intervals (CI), and the P-value of the 
Wald X2 statistic. The two-sided level of significance was set at 0.05. 
 
In addition, a second set of multiple linear regression models were assessed whereby age 
was treated as a continuous variable. The models were supported by histograms to 
investigate the relationship between age and the EORTC QLQ-C30 scores.  
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For those cancer sites with the highest number of observations, EORTC QLQ-C30 mean 
scores adjusted for gender, WHO PS and distant metastasis were calculated for each 
cancer site individually using multiple linear regression models. 
  
All analyses were performed with SAS (version 9.1.3) and Stata 13.  
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Results  
 
General Population Cohorts 
Details for each population sample are shown in Table 1.   
 
INSERT Table 1. 
 
Cancer Cohorts 
Valid baseline HRQOL data in the cancer cohort was available for 6,106 of the 8,201 
(75%) patients who participated in the selected trials. We excluded further patients older 
than 89 and younger than 18 cases from analysis due to a low number of observations 
(n<5) for each excluded age. The distribution of socio-demographic and clinical 
characteristics for each age group is reported in Table 2. The age of the analyzed cancer 
patients ranged from 18-89 years with a mean of 54.47 years. The youngest age group 
(<50) accounted for 33,2% (2,001/6,024) of the cancer cohort, the middle age group for 
57,7% and the oldest age group for only 9,1 %. The age distribution differed across the 
included cancer sites; as expected, 52.9% of the patients with melanoma were under the 
age of 40 and 44% of the patients with prostate cancer were above the age of 70. For 
4,486 of the 6,024 patients the country of residence was reported. Patients in the included 
trials were selected from 34 countries. A total of 93% came from an EU country. The 
remaining patients came from the U.S.A, New Zealand, Canada, South Africa and 
Australia. 
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INSERT Table 2.  
 
Comparison between cancer and population cohorts 
The mean scores and standard deviations (SD) of the EORTC QLQ-C30 scores for the 
cancer and general population cohorts are shown in Table 3. Role functioning was 
statistically significant and clinically meaningfully ( difference) worse in the cancer 
cohort, in all 3 age categories, and is not mentioned further below. 
Within the youngest age category, cancer patients reported statistically significant worse 
HRQOL for global health status, social and physical functioning and for the symptoms 
nausea and vomiting, pain, insomnia, appetite loss, constipation and financial problems. 
Only the differences regarding social functioning (78.79 vs. 91.04) and financial 
problems (18.01 vs. 5.52) were clinically meaningful  
Within the middle age category, cancer patients reported statistically significant worse 
HRQOL for global health status, social, physical functioning and for the symptoms 
fatigue, nausea/vomiting, appetite loss and constipation. Only appetite loss (18.71 vs 
4.92) was clinically meaningful. 
For the oldest age category, cancer patients reported statistically significant worse 
HRQOL for emotional functioning, nausea/vomiting, constipation and appetite loss. Only 
the differences with respect to emotional functioning (81.93-71.23), appetite loss (25.69-
8.65) and constipation (23.85-12.38) were clinically meaningful. 
 
INSERT Table 3. 
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Multiple Linear Regression Models 
The results of the linear regression models with age as a categorical variable are reported 
in Table 4. The table reports the regreVVLRQFRHIILFLHQWVȕ&,DQG3-value for the models 
assessing the association between the EORTC QLQ-C30 scores and age categories 
adjusted for gender, WHO PS, metastatic status. Cancer patients reported a statistically 
significantly worse HRQOL with increasing age for physical and cognitive functioning 
and constipation. Cancer patients reported a statistically significant better HRQOL with 
increasing age for social, role and emotional functioning and the symptoms insomnia and 
financial problems. 
 
Men compared to women reported statistically significant HRQOL impairment for all the 
functional scales and fatigue, nausea and vomiting, insomnia, appetite loss and 
constipation, however none were clinical meaningful (data not shown). For all the 
EORTC QLQ-C30 scores, cancer patients with a poor WHO PS reported a significant 
deterioration in HRQOL. For global health status, social, physical and role functioning 
and appetite loss the difference was higher than 10 points. Distant metastasis has a 
statistical significant negative impact on HRQOL, except for emotional functioning and 
financial problems, however none were clinical meaningful.  
 
INSERT Table 4. 
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Within the cancer cohort, we plotted the average means scores for the EORTC QLQ-C30 
scales against age as a continuous variable (see Figure 1. and 2. online only). The plots 
demonstrate the linear relationship between HRQOL with increasing age.  
 
Table 5 reports the regreVVLRQFRHIILFLHQWV ȕ&,DQG3-value for the models assessing 
the association between the EORTC QLQ-C30 scores and age as continuous variable 
adjusted for gender, WHO PS, metastatic status and stratified by cancer site. Cancer 
patients reported a statistically significant worse HRQOL with increasing age for physical 
and cognitive functioning and constipation. Cancer patients reported a statistical 
significant better HRQOL with increasing age for social, role and emotional functioning 
and financial problems. 
 
Women and men reported statistically significant HRQOL impairment except for role 
functioning, pain, dyspnea and diarrhea however none were clinical meaningful. For all 
the EORTC QLQ-C30 scores, cancer patients with a poor WHO PS reported a significant 
deterioration in HRQOL. For global health status, social, physical and role functioning, 
pain and appetite loss the difference was higher than 10 points. Distant metastasis has a 
statistical significant negative impact on HRQOL, except for emotional functioning and 
financial problems, however none of them were clinical meaningful.  
 
INSERT Table 5. 
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Our data also allows for comparison between different cancer groups, after adjusting for 
gender, WHO PS and distant metastasis. Table 6 shows the mean scores for the three 
most prevalent cancer sites in our database; melanoma (2,112 patients), colorectal (1,141 
patients) and lung cancer (940 patients). HRQOL burden changed with age for each 
cancer site, but the magnitude and size differed between cancer sites. Statistically 
significant HRQOL worsening by age group was seen in the melanoma cohort for seven 
subscales, in the colorectal cohort for three subscales. Within the lung cancer group, only 
the scale financial problems was statistically and clinically (25.60 vs. 12.68) significant 
different between the age groups, whereby financial problems were worse in younger 
patients.  
 
INSERT Table 6. 
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Discussion  
 
Our study shows that cancer patients generally have worse HRQOL compared to the 
general population, but the specifically impaired HRQOL domains vary by age. When 
comparing the cancer versus the general population cohort, role functioning is lower in 
all age categories. Young cancer patients have worse financial problems and social 
functioning, while older cancer patients have more appetite loss, constipation, and poorer 
emotional functioning. Within the cancer cohort, after adjusting for confounding 
variables, HRQOL was worse with increasing age for physical and cognitive functioning, 
and constipation, and better with increasing age for social, role and emotional 
functioning, insomnia and financial problems. Overall, our modelling supports the 
general findings that the impact of ageing on the QLQ-C30 scale scores follows a linear 
relationship. Our study confirms previous studies24,25,26  that the health status of a cancer 
patient is influenced by not only age, but also by disease stage, gender and WHO 
performance status.  
 
Within the cancer cohort, HRQOL differences by age do not appear to be clinical 
relevant. Snöbohm et al.27 mentioned that younger people experience their cancer 
differently than older cancer patients due to a lack of previous experience of severe 
illness. Previous studies28,29 have revealed that it is easier for older people to accept 
physical decrements. For the younger people, any reduce in physical activity due to a 
chronic illness is perceived far more negatively. This might also explain why the elderly 
score higher on some of the functioning scales.  In addition, not being able for younger 
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cancer patients to fulfil the social expectations causes a sense of disappointment and loss, 
resulting in a poorer HRQOL. A paper published by Krok et al.30 suggests that older 
patients have more effective coping mechanisms to help them manage their pain. This 
might explain why pain scores are higher for the younger patients compared to the eldest 
group, however the younger age group had more patients with metastatic cancer, found to 
be significantly associated with HRQOL impairment in our study (models not shown). 
 
A limitation of this study is that we did not have detailed data on general health/frailty 
status as measured by a geriatric assessment in the older population, and no information 
on comorbidity in either cohort. Frailty is a crucial aspect of older persons, with major 
impact on HRQOL and outcome. Several guidelines indicate the need for systematic 
geriatric evaluation in older cancer patients.31,32 Increasing age is associated with 
comorbidity, which has a negative impact on HRQOL33, especially in cancer patients.34,35 
However, comorbidity is frequently an exclusion factor in randomized controlled trials. It 
is likely that the elderly in the cancer cohort reported here have a better overall health 
status than their counterparts in the general population cohort. Another limitation is that 
our general population cohorts are based on a selected population from specific countries 
and therefore not necessary matching a non-cancer population or a wider population as 
the right reference group for our cancer cohorts. Also within the cancer cohorts, our data 
is limited to a selection of cancer trials with their own selection and eligibility criteria and 
therefore not necessarily representative for all cancer trials. Our cancer specific models 
demonstrate that the HRQOL outcomes can be very depending on the cancer group, but 
most likely this is driven by the selected trials for each group with each their own specific 
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in- and exclusion criteria. Although our models were stratified for cancer site to account 
for these between cancer differences, there is still a chance that the HRQOL differences 
are related to selected cancer groups and trials. 
 
The content validity of the EORTC QLQ-C30 for an elderly population could be open to 
debate.  The EORTC Quality of Life Elderly Task Force36 and the EORTC Quality of 
Life Group developed a new HRQOL questionnaire for elderly cancer patients given that 
the EORTC-QLQ-C30 was developed using data from generally younger patients. A 
systematic literature review by Fitzsimmons et al.37 suggests that the concerns of older 
patients differ from those of younger patients; a specific module may be needed to 
capture the needs and concerns most relevant to them.   
 
Our results suggest that treatment decisions should also include HRQOL.38 Currently, 
many elderly patients are excluded from certain treatments because of their age or by 
stringent physical conditions. However, judgment of fitness for treatment would ideally   
LQFRUSRUDWHDSDWLHQW¶V+542/39 and coping mechanism, rather than age or performance 
status (PS) alone as demonstrated in this study. Available evidence suggests40 that elderly 
patients can derive similar survival benefits from aggressive treatments as younger 
patients. A systematic assessment of HRQOL at baseline may allow physicians to select 
appropriate elderly patients and reduce underutilization of aggressive treatments. 
 
By demonstrating the age-related differences in HRQOL, even among a highly selected 
group of elderly patients included in clinical trials (those likely to have minimal 
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comorbidity), this study supports the need to include the elderly in clinical trials where 
accurate measurement of HRQOL is a focus. Trials of lower-toxicity treatment strategies, 
or of low risk supportive care interventions, could be designed specifically for older 
patients where the focus is not efficacy, but maintaining active life expectancy; the 
average number of years of life remaining in an independent state ±i.e., free from 
significant disability.41, 42  Biologic agents with less toxic effects, focused on stabilization 
of disease, may be tailor-made for the elderly. Delay of disease progression should be 
combined with a proper HRQOL assessment to determine the overall benefit of such a 
drug.  $QRWKHU RSWLRQ PLJKW EH WR HQUROO ROGHU SDWLHQWV LQ VPDOOHU ³VXE-WULDOV´ ZLWKLQ
bigger trials or to design end points specifically for older patients, which could include 
HRQOL endpoints such as physical functioning which are equally important for the 
elderly than extending survival.17 However more longitudinal and observational studies, 
with no stringent inclusion criteria, are needed to confirm these statements. 
 
The inclusion of HRQOL endpoints can also lead to shared decision making by 
physicians and patients.43  This is also acknowledged by EORTC elderly task force, the 
US Food and Drug Administration in its Guideline for the Study of Drugs Likely to Be 
Used in the Elderly44 and in the mission statement of the Cancer and Aging Research 
Group in collaboration with the National Cancer Institute.45 As expected, many sources 
are now showing that cancer is becoming a chronic disease and a disease something for 
the elderly. Our evidence shows support for the many health needs these patients have 
and society needs to take urgent action to assure that these growing number of patients 
receive their health needs. 
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TABLES 
 
Table 1. Distribution (N=actual numbers; %=percentage) of age and gender for the five general population cohorts.  
Variables Norwegian cohort German cohort German cohort Dutch cohort Swedish cohort N=1,965 N=2,208 N=4,684 N=1,731 N=4,910 
Age (years)   
Mean (Min-Max) 47.4 (19-93) 49.4 (16-92) 51.8 (NA)* 52.90 (NA) 65 (40-49) 
Age (categories) 
<50 1,100 (56%) 1,014 (50%) 2,112 (45%) 690 (40%) 410 (8%) 
<=50 and <=70  550 (28%) 730 (36%) 1,539 (33%) 766 (44%) 2,615 (53%) 
>70 315 (16%) 284 (14%) 1,033 (22%) 275 (16%) 1,903 (39%) 
Men 1,022 (52%) 892 (44%) 2,050 (44%) 935 (54%) 3,224 (66%) 
*NA=Not available 
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Table 2. Distribution (N=actual numbers; %=percentage) of socio-demographic and clinical variables in the cancer cohort for 
the three age categories: <50; 50-70; >70.  
Variables Category Age <50 Age <=50 and Age <=70 Age > 70  N=2,001  N=3,476 N=547 
Performance Status  
 
WHO 0-1 1,704 (85.2%)                 3,130 (90.0%)                  443 (80.9%)                   
WHO 2-3   55 (2.7%)                       242 (7.0%)                      96 (17.6%)                     
Unknown  242 (12.1%)                    104 (3.0%)                        8 (1.5%)                       
Distant Metastases                                                                                                                                                                                            
 
Yes 1,377 (68.8%)                 1,868 (53.7%)                  120 (21.9%)                   
No  338 (16.9%)                   1,370 (39.4%)                  402 (73.5%)                   
Unknown  286 (14.3%)                    238 (6.9%)                       25 (4.6%)                      
Gender                                                                                                                                                                                                                          
 
Female 1,118 (55.9%)                 2,243 (64.5%)                  426 (77.9%)                   
Male  883 (44.1%)                   1,231 (35.4%)                  121 (22.1%)                   
Unknown    0 (0.0%)                          2 (0.1%)                          0 (0.0%)                       
Cancer site                                                                                                                                                                                                            
 
Colorectal  174 (8.70%)                    807 (23.22%)                  160 (29.25%)                 
Lung  210 (10.49%)                  676 (19.45%)                   54 (9.87%)                    
Esophageal   14 (0.70%)                      44 (1.27%)                       7 (1.28%)                     
Ovarian   48 (2.40%)                     140 (4.03%)                     14 (2.56%)                    
Prostate   11 (0.55%)                     290 (8.34%)                    224 (40.95%)                 
Testicular  223 (11.14%)                   10 (0.29%)                       0 (0.0%)                       
Breast  160 (8.00%)                    145 (4.17%)                     16 (2.93%)                    
Head & Neck   94 (4.70%)                     278 (8.0%)                       21 (3.84%)                    
Melanoma 1,059 (52.9%)                 1,010 (29.06%)                 43 (7.86%)                    
Pancreas    8 (0.40%)                       76 (2.19%)                       8 (1.46%)                     
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Table 3. EORTC QLQ-C30 unadjusted mean scores for the cancer and the general population cohort for the three age 
categories <50; 50-70; >70.  
   
Observed Mean Scores 
Age < 50 Age <=50 and Age <=70 Age > 70 
Cancer 
cohort 
General 
Populatio
n cohort P-value 
Cancer 
cohort  
General 
Populatio
n cohort P-value 
Cancer 
cohort  
General 
Populati
on 
cohort P-value 
Mean (SD) Mean (SD) Mean (SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
EORTC QLQ-C30 Functioning ScalesÁ 
Global Health 
Status 
66.20  
(21.99) 
75.41  
(3.48) 0.0043 
61.77  
(23.19) 
71.72  
(5.71) 0.0176 
57.41 
(23.13) 
66.25 
(9.12) 0.0861 
Social 
Functioning 
78.69  
(25.31) 
91.04  
(4.36) 0.0033 
77.68  
(27.83) 
87.47  
(5.35) 0.015 
78.90 
(26.11) 
83.83 
(7.79) 0.211 
Physical 
Functioning 
85.76  
(20.60) 
94.42  
(1.75) 0.0004 
78.72  
(24.19) 
87.2  
(3.18) 0.004 
68.53 
(27.03) 
74.99 
(6.59) 0.08 
Role 
Functioning 
71.35  
(31.19) 
91.84  
(3.99) 0.0003 
69.73  
(32.42) 
85.73  
(5.56) 0.0031 
65.42 
(34.91) 
77.02 
(8.98) 0.0415 
Emotional 
Functioning 
72.15  
(22.85) 
79.23  
(8.58) 0.1444 
70.45  
(23.60) 
80.14  
(8.22) 0.0584 
71.31 
(23.60) 
81.93 
(8.11) 0.0466 
Cognitive 
Functioning 
88.91  
(17.54) 
90.24  
(4.41) 0.5374 
87.10  
(18.59) 
88.20  
(3.33) 0.5002 
83.53 
(20.05) 
82.87 
(4.63) 0.8456 
EORTC QLQ-C30 Symptom Scales 
Fatigue 26.81  (24.27) 
21.34  
(9.00) 0.2539 
32.03  
(26.85) 
22.81  
(6.65) 0.0364 
39.44 
(27.52) 
30.51 
(8.98) 0.0907 
Nausea/Vomi
ting 
5.31  
(13.88) 
3.54  
(0.96) 0.0164 
6.86  
(16.44) 
3.10  
(1.11) 0.0016 
9.45  
(19.27) 
4.25  
(1.42) 0.0016 
Pain 23.76  (26.41) 
14.80  
(5.75) 0.0266 
27.24  
(29.41) 
23.1  
(6.03) 0.1996 
32.26 
(30.61) 
28.62 
(9.67) 0.3649 
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Dyspnea 11.54  (21.55) 
8.34  
(4.56) 0.2045 
17.06  
(25.44) 
12.63  
(4.63) 0.0991 
22.30 
(27.35) 
22.26 
(6.78) 0.9703 
Insomnia 24.39  (29.25) 
15.79  
(6.14) 0.0368 
28.95  
(31.48) 
23.53  
(7.86) 0.1984 
28.89 
(30.77) 
27.17 
(9.43) 0.5485 
Appetite loss 12.42  (23.82) 
5.64  
(2.65) 0.0048 
18.71  
(29.68) 
4.92  
(2.01) 0.0001 
25.69 
(34.23) 
8.65  
(4.45) 0.0011 
Constipation 8.55  (20.65) 
4.56  
(2.43) 0.0225 
14.84  
(26.57) 
7.32  
(3.06) 0.0053 
23.85 
(31.82) 
12.38 
(5.72) 0.0094 
Diarrhea 6.34  (15.97) 
6.32  
(3.11) 0.9741 
6.81  
(17.81) 
6.33  
(3.30) 0.7592 
8.34 
(18.99) 
6.75 
(3.19) 0.4557 
Financial 
Problems 
18.06  
(28.33) 
5.52  
(2.7) 0.0005 
12.62  
(25.28) 
8.74  
(4.83) 0.1473 
7.88 
(19.53) 
8.74 
(6.16) 0.7202 
Á+LJKHUVFRUHVLQGLFDWHEHWWHUIXQFWLRQLQJDQG*OREDO+HDOWK6WDWXV+LJKHUVFRUHVLQGLFDWHPRUHV\PSWRPV 
Bold values indicate statistically significant, and clinically meaningful differences between cancer and general population for 
each age category 
QLQ-C30=the European Organisation for Research and Treatment of Cancer quality-of-life core questionnaire 
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Table 4. Multiple linear regression models in the cancer cohort UHSRUWLQJWKHUHJUHVVLRQFRHIILFLHQWVȕ&,DQGS-value for the 
fifteen models assessing the association between the EORTC QLQ-C30 scores and three age categories (<50; 50-70; >70) 
adjusted for gender, WHO PS, metastatic status stratified by cancer site. 
 
Variables 
Age group 
(<50;<=50 and <=70; 
>70) 
Gender 
(men vs women) 
WHO PS 
(good vs poor) 
Distant metastasis 
(no vs yes) 
 
ȕ*  
(CI)** P-value 
ȕ  
(CI) P-value 
ȕ  
(CI) P-value 
ȕ  
(CI) P-value 
EORTC QLQ-C30 Functioning ScalesÁ 
Global Health 
Status 
-0.03 
(-2.24;1.63) 0.757 
-4.2 
(-5.19;-2.86) <0.001 
-10.93 
(-11.90;-9.96) <0.001 
-1.85 
(-3.07;-0.64) 0.003 
Social 
Functioning 
6.84 
( 4.38-9.30)  <0.001 
-2.55 
(-3.98;-1.13) <0.001 
-11.4 
(-12.59;-10.21) <0.001 
-3.13 
(-4.62;-1.65) <0.001 
Physical 
Functioning 
-4.37 
(-6.28;-2.46)  <0.001 
-3.58 
(-4.73;-2.43) <0.001 
-13.84 
(-14.80;-12.88) <0.001 
-5.62 
(-6.82;-4.43) <0.001 
Role  
Functioning 
2.86 
(0.075;5.65) 0.004 
-2.04 
(-3.71;-0.37) 0.017 
-15.13 
(-16.52;-13.73) <0.001 
-3.19 
(-4.93;-1.44) <0.001 
Emotional 
Functioning 
3.18 
(1.03;5.33) 0.004 
-5.67 
(-6.92;-4.43) <0.001 
-5.64 
(-6.69;-4.61) <0.001 
-0.07 
(-1.37;1.22) 0.914 
Cognitive 
Functioning 
-1.72 
(-3.42;-0.02) 0.047 
-3.06 
(-4.05;-2.08) <0.001 
-5.997 
(-6.80;-5.15) <0.001 
-1.46 
(-2.49;-0.44) 0.005 
EORTC QLQ-C30 Symptom Scales 
Fatigue 0.84 (-1.30;2.99) 0.44 
5.08 
(3.79;6.38) <0.001 
13.61 
(12.53;14.69) <0.001 
5.33 
(3.99;6.67) <0.001 
Nausea/Vomiting -0.17 (-1.54;1.19) 0.802 
2.51 
(1.69;3.33) <0.001 
5.49 
(4.81;6.17) <0.001 
2.52 
(1.66;3.37) <0.001 
Pain -1.65 (-4.06;0.75) 0.178 
0.11 
(-1.33;1.55) 0.881 
15.53 
(14.32;16.73) <0.001 
5.31 
(3.80;6.81) <0.001 
Dyspnoea 1.91 0.076 -0.08 0.894 7.65 <0.001 -2.93 <0.001 
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 (-0.20;4.03) (-1.36;1.18) (6.59;8.72) (-4.25;-1.60) 
Insomnia -4.15 
 (-6.88;-1.43) 0.003 
2.73 
(1.09;4.36) 0.001 
8.86 
(7.49;10.22) <0.001 
3.06 
(1.36;4.77) <0.001 
Appetite loss 0.26 (-2.11;2.65) 0.825 
3.61 
(2.18;5.05) <0.001 
13.93 
(12.73;15.12) <0.001 
4.48 
(2.99;5.97) <0.001 
Constipation 5.62 (3.36;-7.88) <0.001 
1.97 
(0.62;3.33) 0.004 
7.67 
(6.54;8.80) <0.001 
6.88 
(5.47;8.30) <0.001 
Diarhoea -0.41 (-1.97;1.13) 0.601 
-0.78 
(-1.72;0.15) 0.098 
0.81 
(0.03;1.59) 0.041 
1.32 
(0.35;2.29) 0.008 
Financial 
Problems 
-8.64 
(-11.09;6.19)  <0.001 
-0.95 
(-2.38;0.47) 0.188 
4.22 
(3.03;5.41) <0.001 
-0.24 
(-1.73;1.24) 0.749 
*ȕ = Regression coefficient ** CI = Confidence Intervals 
Á+LJKHUVFRUHVLQGLFDWHEHWWHUIXQFWLRQLQJDQG*OREDO+HDOWK6WDWXV+LJKHUVFRUHVLQGLFDWHPRUHV\PSWRPV 
QLQ-C30=the European Organisation for Research and Treatment of Cancer quality-of-life core questionnaire 
Bold values indicate significantly worse HRQOL components with increasing age 
Italic values indicate significantly better HRQOL components with increasing age 
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Table 5. Multiple linear regression models UHSRUWLQJWKHUHJUHVVLRQFRHIILFLHQWVȕ&,DQGS-value for the fifteen models 
assessing the association between the EORTC QLQ-C30 scores and age adjusted for gender, WHO PS, metastatic status 
stratified by cancer site 
 
Variables 
Agegroup 
(<50;<=50 and <=70; 
>70) 
Gender 
(men vs women) 
WHO PS 
(good vs poor) 
Distant metastasis 
(no vs yes) 
 
Ǻ 
(CI)** P-value 
Ǻ 
(CI) P-value 
Ǻ 
(CI) P-value 
Ǻ 
(CI) 
P-
value 
EORTC QLQ-C30 Functioning ScalesÁ 
Global Health 
Status 
-0.02 
 (-0.07;0.019) 0.238 
-4.12 
(-5.29;-2.95) <0.001 
-10.87 
(-11.84;-9.89) <0.001 
-1.77 
(-2.99;-0.56) 0.004 
Social 
Functioning 
0.019 
(0.13-0.25)  <0.001 
-2.25 
(-3.68;-0.82) 0.002 
-11.51 
(-12.68;-10.32) <0.001 
-3.28 
(-4.77;-1.79) <0.001 
Physical 
Functioning 
-0.14 
 (-0.19;-0.09)  <0.001 
-3.85 
(-5.01;-2.70) <0.001 
-13.72 
(-14.68;-12.76) <0.001 
-5.46 
(-6.65;-4.26) <0.001 
Role  
Functioning 
0.18 
 (0.12;0.25)  <0.001 
-1.47 
(-3.15;0.21) 0.087 
-15.51 
(-16.91;-14.12) <0.001 
-3.65 
(-5.39;-1.90) <0.001 
Emotional 
Functioning 
0.04 
 (-0.01;0.09) 0.121 
-5.72 
(-6.97;-4.46) <0.001 
-5.55 
(-6.60;-4.51) <0.001 
0.018 
(-1.28;1.32) 0.978 
Cognitive 
Functioning 
-0.06 
 (-0.10;-0.02) 0.002 
-3.19 
(-4.18;-2.21) <0.001 
-5.9 
(-6.72;-5.07) <0.001 
-1.38 
(-2.40;-0.35) 0.008 
EORTC QLQ-C30 Symptom Scales 
Fatigue -0.01 
 (-0.05;0.05) 0.973 
5.02 
(3.72;6.32) <0.001 
13.68 
(12.60;14.76) <0.001 
5.4 
(4.05;6.75) <0.001 
Nausea/Vomiting -0.01 
 (-0.04;0.02) 656 
2.49 
(1.66;3.32) <0.001 
5.5 
(4.82;6.18) <0.001 
2.53 
(1.68;3.39) <0.001 
Pain -0.02 
 (-0.08;0.03) 0.419 
0.12 
(-1.33;1.58) 0.867 
15.48 
(14.27;16.69) <0.001 
5.27 
(3.76;6.78) <0.001 
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Dyspnoea 0.04 
 (-0.01;0.09) 0.114 
-0.04 
(-1.32;1.24) 0.947 
7.66 
(6.60;8.73) <0.001 
-2.93 
(-4.26;-1.60) <0.001 
Insomnia -0.01 
 (-0.06;0.06) 0.983 
3.02 
(1.36;4.67) <0.001 
8.55 
(7.18;9.92) <0.001 
2.74 
(1.03;4.45) 0.002 
Appetite loss 0.03 
 (-0.02;0.09) 0.264 
3.74 
(2.29;5.18) <0.001 
13.84 
(12.64;15.04) <0.001 
4.38 
(2.88;5.87) <0.001 
Constipation 0.21 
 (0.16;0.27)  <0.001 
2.46 
(1.11;3.83) <0.001 
7.39 
(6.27;8.53) <0.001 
6.54 
(5.13;7.96) <0.001 
Diarhoea -0.02 
 (-0.06;0.01)  0.136 
-0.88 
(-4.82;0.06) 0.066 
87 
(0.09;1.65) 0.028 
1.39 
(0.42;2.37) 0.005 
Financial 
Problems 
-0.37 
 (-0.43;-0.31)  <0.001 
-1.82 
(-3.24;-0.41) 0.12 
4.75 
(3.57;5.93) <0.001 
0.39 
(-1.08;1.86) 0.604 
*Regression coefficient ** Confidence Intervals 
Á+LJKHUVFRUHVLQGLFDWHEHWWHUIXQFWLRQLQJDQG*OREDO+HDOWK6WDWXV+LJKHUVFRUHVLQGLFDWHPRUHV\PSWRPV 
QLQ-C30=the European Organisation for Research and Treatment of Cancer quality-of-life core questionnaire 
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Table 6. Multiple linear regression models reporting mean scores by age categories (<50; 50-70; >70)  for the EORTC QLQ-
C30 scores adjusted for gender, WHO PS, metastatic status for the cancer groups melanoma, colorectal and lung. 
Populations 
Adjusted Mean Scores 
P-
Value 
Adjusted Mean Scores 
P-
Value 
Adjusted Mean Scores 
P-
Value 
Melanoma Cancer 
(N=2,112) 
Colorectal Cancer 
(N=1,141) 
Lung Cancer 
(N=940) 
 
Age 
<50 
N= 
1059 
Age 
<=50 
and Age 
<=70 
N=1010 
Age 
>70 
N=43 
Age 
<50 
N=174 
Age 
<=50 
and Age 
<=70 
N=807 
Age 
>70 
N=16
0 
Age 
<50 
N=210 
Age 
<=50 
and 
Age 
<=70 
N=676 
Age 
>70 
N=54 
EORTC QLQ-C30 Functioning ScalesÁ 
Global Health Status 55.04 54.50 58.12 0.439 49.68 53.10 52.92 0.191 52.50 50.96 52.79 0.668 
Social Functioning 72.28 74.51 80.89 0.011 61.43 67.47 72.81 0.002 62.73 65.63 70.63 0.226 
Physical Functioning 76.03 73.54 73.23 0.006 64.61 66.48 63.34 0.258 63.42 62.57 57.97 0.372 
Role Functioning 67.19 70.86 76.46 0.009 53.48 57.59 58.10 0.297 55.77 53.73 44.43 0.109 
Emotional 
Functioning 73.73 73.69 78.36 0.385 60.14 63.41 63.48 0.269 62.88 61.29 63.77 0.648 
Cognitive 
Functioning 94.61 93.95 90.44 0.176 80.75 80.65 78.94 0.594 82.99 82.63 82.39 0.973 
EORTC QLQ-C30 Symptom Scales 
Fatigue 45.76 45.75 46.40 0.567 48.05 46.76 47.06 0.854 46.68 46.17 51.20 0.457 
Nausea/Vomiting 10.14 9.49 13.25 0.017 16.58 13.58 12.54 0.061 12.45 11.99 9.10 0.463 
Pain 44.70 44.15 41.30 0.598 41.35 34.65 28.54 0.001 44.91 42.49 38.25 0.384 
Dyspnoea 20.11 20.95 21.12 0.478 24.34 20.20 21.24 0.167 38.59 38.57 50.94 0.031 
Insomnia 45.33 47.36 44.37 0.212 41.48 35.56 33.80 0.063 37.94 36.02 34.72 0.757 
Appetite loss 54.12 53.71 64.19 0.001 34.61 33.83 36.55 0.597 34.39 35.86 30.58 0.539 
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Constipation 4.36 6.91 4.54 0.007 20.56 19.11 24.08 0.140 16.54 18.24 21.27 0.488 
Diarhoea 4.12 2.86 4.27 0.077 14.01 11.75 8.23 0.085 5.53 5.18 4.39 0.904 
Financial Problems 7.96 2.78 0.35 <.001 22.87 15.35 10.88 <.001 25.60 19.35 12.68 0.006 
Á+LJKHUVFRUHVLQGLFDWHEHWWHUIXQFWLRQLQJDQG*OREDO+HDOWK6WDWXV+LJKHUVFRUHVLQGLFDWHPRUHV\PSWRPV 
QLQ-C30=the European Organisation for Research and Treatment of Cancer quality-of-life core questionnaire 
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Figures 
 
Figure 1. Mean EORTC QLQ-C30 scores across age for the functioning scales (online only) 
Legend: Higher scores indicate better functioning and Global Health Status 
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Figure 2. Mean EORTC QLQ-C30 scores across age for the symptom scales (online only) 
Legend: Higher scores indicate more symptoms 
 
 
